Middle dose level:infuse 5.0×10^6 CAR+ T Cells/kg

2 trials

Sponsors

The First Affiliated Hospital of Zhengzhou University, Hebei Yanda Lu Daopei Hospital

Conditions

Advanced non-small cell lung cancer (squamous cell carcinoma) , head and neck squamous cell carcinoma and melanomarefractory/relapsed Positive CD19+ B-cell malignant lymphoma

Early Phase 1

Clinical trial of safety and efficacy of CD19 chimeric antigen receptor T cell in the treatment of refractory/relapsed Positive B-cell malignant lymphoma

Active, not recruitingChiCTR2000034575

Hebei Yanda Lu Daopei Hospitalrefractory/relapsed Positive CD19+ B-cell malignant lymphoma

Start: 2020-08-30Updated: 2020-07-20

Unknown Phase

Phase I / II Clinical Study for the Safety and Effectiveness of Chimeric Antigen Receptor T Cells in Subjects with Advanced Tumors

Active, not recruitingChiCTR1900027852

The First Affiliated Hospital of Zhengzhou UniversityAdvanced non-small cell lung cancer (squamous cell carcinoma) , head and neck squamous cell carcinoma and melanoma

Start: 2020-02-01Updated: 2019-12-10